SMARCA4 and cancer: PRT3789 is another potent and selective SMARCA2-targeted degrader that demonstrated synthetic lethality in SMARCA4-deficient cancers in vitro and in vivo and is currently in Phase I clinical trials for patients with SMARCA4 mutant solid tumors that express SMARCA2 [127].